Table 2.
Expression of RIT targets in PDAC.
| Target | Antibody | Expression in PDAC Cells or Tissues | Measurement Type | References |
|---|---|---|---|---|
| B7-H3 | Anti-B7-H3 (1027) | 88.2% (60/68) | IHC | Loos et al. [24] |
| CA19-9 | 5B1 CA19-9 |
77.7% (7/9) 90.7% (39/43) |
IHC IHC |
Viola-Villegas et al. [25] Shi et al. [26] |
| CD147 | MEM-M6/1 and HIM6 combination | 87.2% (34/39) | IHC | Riethdorf et al. [27] |
| CEA | Anti-CEA | 89.2% (223/250) | IHC | Yamaguchi et al. [28] |
| CENT 1 | Anti-CENT 1 | 50.0% (10/20) | IHC | Jiao et al. [29] |
| EGFR | Anti-EGFR (H11) | 88.5% (92/104) | IHC | Al-Ejeh et al. [6] |
| Ferritin | Bz-DTPA-AMB8LK | 52% (CAPAN-1 cells) | Immunoreactivity | Sabbah et al. [30] |
| HER 2 | Anti-HER 2 | 59.9% (124/207) | IHC | Harder et al. [31] |
| Integrin avß5 | 14C5 | 100 (4/4) | IHC | Vervoort et al. [32] |
| Integrin α6β4 | ITGA6B4 | 55% (range: 13.1–91.0% across four cell lines) | Flow cytometry | Aung et al. [33] |
| 439-9B | 92.0% (104/113) | IHC | Cruz-Monserrate et al. [34] | |
| MUC1 | C595 MA5 |
90.5% (48/53) 100% (43/43) |
IHC IHC |
Qu et al. [35] Shi et al. [26] |
| MUC1/MUC5AC | PAM4 | 79.1% (34/43) | IHC | Shi et al. [26] |
| PDGFR-β | Anti-PDGFR-β | 100% (5/5) | IHC | Hwang et al. [36] |
| TRFC | Anti-TFRC (Ber-T9) | 80.4% (41/51) | IHC | Ryschich et al. [13] |
| uPA/uPAR | PAI2 | 87% (26/30) | IHC | Qu et al. [37] |
CA19-9: carbohydrate antigen 19.9, CEA: carcinoembryonic antigen, CENT 1: centrin 1, EGFR: epidermal growth factor receptor, HER 2: human epidermal growth factor receptor 2, MUC1: mucin 1, MUC5AC: mucin 5AC, PDGFR- β: platelet-derived growth factor receptor beta, TRFC: transferrin receptor, uPA/uPAR: urokinase plasminogen activator/urokinase plasminogen activator receptor, PAI2: plasminogen activator inhibitor 2, and IHC: immunohistochemistry.